AbbVie Inc (ABBV)

64.57
0.50 0.78
NYSE : Health Care
Prev Close 64.07
Open 64.00
Day Low/High 63.69 / 64.75
52 Wk Low/High 45.45 / 68.12
Volume 4.34M
Avg Volume 7.10M
Exchange NYSE
Shares Outstanding 1.63B
Market Cap 105.82B
EPS 3.10
P/E Ratio 18.73
Div & Yield 2.28 (3.50%)

Latest News

Stocks Fall as Health Care Slumps Ahead of Presidential Debate

Stocks Fall as Health Care Slumps Ahead of Presidential Debate

Stocks are lower Monday as Wall Street's attention shifts to the looming presidential debate from central bank policy.

AbbVie Showcases Commitment To Research And Innovation In Dermatology At The 25th European Academy Of Dermatology And Venereology Congress

AbbVie Showcases Commitment To Research And Innovation In Dermatology At The 25th European Academy Of Dermatology And Venereology Congress

- New Phase 2 open-label extension data to be presented on investigational biologic compound risankizumab, an anti-IL-23 monoclonal antibody, currently under investigation for moderate to severe chronic plaque psoriasis

AbbVie Announces Submission Of A Supplemental New Drug Application For Ibrutinib (IMBRUVICA®) For Treatment Of Marginal Zone Lymphoma

AbbVie Announces Submission Of A Supplemental New Drug Application For Ibrutinib (IMBRUVICA®) For Treatment Of Marginal Zone Lymphoma

- If approved by the U.S. FDA, ibrutinib will be the first therapy specifically approved for patients with marginal zone lymphoma (MZL), a slow-growing form of non-Hodgkin's lymphoma, and the fifth new treatment indication for the medication

AbbVie Presents Data On Eight-Week Treatment Of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) + EXVIERA® (dasabuvir Tablets) In Patients With Genotype 1b Chronic Hepatitis C

AbbVie Presents Data On Eight-Week Treatment Of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) + EXVIERA® (dasabuvir Tablets) In Patients With Genotype 1b Chronic Hepatitis C

- 98 percent of previously untreated genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected patients without cirrhosis achieved SVR12 in Phase 3b GARNET study1

AbbVie Is Gaining Traction -- Here's How to Trade It From Here

AbbVie Is Gaining Traction -- Here's How to Trade It From Here

AbbVie's impressive move is setting the stage for an upside breakout.

Post Fed Meeting, Dividend Stocks Rule

The key is to focus on names with steadily growing earnings and dividends.

AbbVie (ABBV) Stock Gains on BioArctic Parkinson's Collaboration

AbbVie (ABBV) Stock Gains on BioArctic Parkinson's Collaboration

AbbVie (ABBV) announced on Tuesday that it would partner with BioArctic Neuroscience to develop and commercialize BioArctic's Parkinson's treatments.

New Data Presented At ECTRIMS Reinforce Efficacy Of ZINBRYTA™ (Daclizumab) And Support Long-Term Safety Profile

New Data Presented At ECTRIMS Reinforce Efficacy Of ZINBRYTA™ (Daclizumab) And Support Long-Term Safety Profile

A new post-hoc analysis from the pivotal DECIDE study shows that a significantly greater number of people treated with ZINBRYTA TM (daclizumab) achieved no evidence of disease activity (NEDA) compared to those taking...

AbbVie's Battle Royale

AbbVie's Battle Royale

Year to date, shares of AbbVie are up 7%. With a gigantic patent battle looming, can the stock go higher?

Big Pharma Spends Millions to Keep Prices High for California Agencies

Big Pharma Spends Millions to Keep Prices High for California Agencies

Drug companies like Merck, Pfizer and Johnson & Johnson are spending big bucks on the opposition of Proposition 61.

5 Healthy Pharma and Biotech Plays

5 Healthy Pharma and Biotech Plays

These stocks look good as seasonal volatility sets in.

'Mad Money' Lightning Round: Abbvie Is a Great Long-Term Position

'Mad Money' Lightning Round: Abbvie Is a Great Long-Term Position

Cramer is sticking with International Paper and likes Advanced Micro Devices.

Jim Cramer's 'Mad Money' Recap: Why You Shouldn't Be Jumping In and Out of Stocks

Jim Cramer's 'Mad Money' Recap: Why You Shouldn't Be Jumping In and Out of Stocks

This is not the time to sell in a panic, Cramer says.

AbbVie Declares Quarterly Dividend

AbbVie Declares Quarterly Dividend

Dive Safely Into These 12 Dividend Payers

Dive Safely Into These 12 Dividend Payers

If and when interest rates go up, this basket of stocks should continue to do well.

AbbVie (ABBV) Stock Retreats, JPMorgan Downgrades

AbbVie (ABBV) Stock Retreats, JPMorgan Downgrades

AbbVie's (ABBV) stock rating was cut to 'neutral' at JPMorgan this morning.

Analysts' Actions -- Apple, Lululemon, Nike, Tractor Supply and More

Analysts' Actions -- Apple, Lululemon, Nike, Tractor Supply and More

Here are Thursday's top research calls, including downgrades for Apple, Lululemon Athletica, Nike and Tractor Supply.

Top 10 Dividend Stocks to Buy in September

Top 10 Dividend Stocks to Buy in September

Each of these companies pays extremely safe dividends, yields over 2%, and doesn't appear to be extremely overvalued like many other dividend-paying stocks in the market today.

These 5 Stocks Are Breaking Out -- Do You Own Them Yet?

These 5 Stocks Are Breaking Out -- Do You Own Them Yet?

Here's a technical look at how to trade some of the biggest stocks on Wall Street.

5 Health Care Stocks John Paulson Is Betting On in 2016

5 Health Care Stocks John Paulson Is Betting On in 2016

When it comes to investing in health care, hedge fund pro John Paulson knows his stuff.

Cramer: The Answer to This Market: Part 1

Cramer: The Answer to This Market: Part 1

The leadership is quite stark.

Pharma Has History of Price Gouging, Mylan Should Be No Surprise

Pharma Has History of Price Gouging, Mylan Should Be No Surprise

While the public seized on Mylan's price increases for EpiPens, the story of a common drug industry practice - increasing prices ahead of generics entering the market - got lost.

Why EpiPen, Why Now? Analysts Explain the Timing of Mylan's Trouble

Why EpiPen, Why Now? Analysts Explain the Timing of Mylan's Trouble

The pharma company has been increasing the price of the epinephrine injector since 2007, so why are people finally taking notice?

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.

Gilead May Be Better Off Splitting Itself in Two, Analysts Say

Gilead May Be Better Off Splitting Itself in Two, Analysts Say

A recent note from RBC Capital on Gilead gained a lot of attention as well as a pickup in call-option purchases.

Should Gilead Split in Two?

Should Gilead Split in Two?

RBC Capital analysts say this would free 'trapped value' on drug treatments.

TG Therapeutics Looks Like a Healthy Play

TG Therapeutics Looks Like a Healthy Play

Small biotech tanked on weak earnings, but still seems promising.